News and Trends 2 Nov 2017 Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes Two Swedish biotechs, Betagenon and Baltic Bio, have announced promising preliminary Phase IIa results for their Type 2 Diabetes candidate. Betagenon develops therapies for chronic energy balance disorders and has received funding from the EU’s program for research and innovation, Horizon 2020. Privately funded Betagenon has partnered up with Baltic Bio to share the profits from a type […] November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Close to Launching Gene Therapy, Dutch Biotech Raises Over $91M on the Nasdaq Update (2/11/2017): uniQure has closed its public offering raising over $91m (€78M) on the Nasdaq, taking advantage of a massive stock jump triggered by the announcement that an improved version of its gene therapy for hemophilia B will enter Phase III trials. Originally published on 24/10/2017 UniQure launched a public offering, perfectly timed with a rise in […] November 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical need. With the announcement of a €18M Series A, it hopes to take begin moving its candidates into the clinic. It had raised €14M thanks to investment from Epidarex […] November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis’ failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize an mRNA drug encoding for the protein hormone relaxin. The therapy has the same target as Novartis’ Serelaxin (RLX030), a drug that was dropped in March […] November 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Infographic: The Berlin Biotech Ecosystem Together with Berlin Partner for Business and Technology, we have created an absolutely amazing infographic full of cool & fun facts about the Berlin Biotech Ecosystem. Click on the image below to view the complete infographic! Do you want to learn more about Berlin and its Biotech ecosystem? Visit Berlin Partner for […] November 2, 2017 - 1 minutemin - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 2 Nov 2017 Meet the Top Biotech Investor Who Picked His Career By Accident Kevin Johnson, Partner at Medicxi, joined us last week for our Meetup in London. He told us how he ended as an investor despite starting in biotech. Fresh from his PhD at Cambridge, Johnson stepped into biotech and led the development of a number of human antibodies at Cambridge Antibody Technology (CAT). The company was eventually responsible for […] November 2, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 1 Nov 2017 Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data. GeNeuro’s stock rose by 30% on Monday following an announcement of promising results from its relapsing-remitting multiple sclerosis drug, GNbAC1. After six months, the highest dose demonstrated an anti-inflammatory effect and seemed to stimulate […] November 1, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2017 Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on Brussels Euronext. Apitope hopes to treat a number of autoimmune diseases affecting many systems throughout the body. The company has developed peptides, ‘apitopes‘, that tackle the immunological basis of the disease. The company has just […] November 1, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2017 Update: Dutch VC Raises €82M for a New European Medical Biotech Fund Update (1/11/2017): BioGeneration Ventures has surpassed its third round goal of raising €75M by securing €82M. The VC has received extra support from Bristol-Myers Squibb and Johnson & Johnson Innovation. Originally published 27/06/2017 BioGeneration Ventures has secured €66M from Dutch and EU investors that will go towards biotechs developing therapeutics, diagnostics and medical devices. BioGeneration Ventures is a Dutch VC that focuses its investments on […] November 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Oct 2017 German Pharmacist Finds a Way to Put the Brakes on Gallbladder Cancer Research has identified a protein that drives tumor growth, which opens up a new therapeutic target for gallbladder cancer. Gallbladder cancer is often detected too late to be treated effectively as it shows few symptoms. Research, published in Oncotarget, has identified a pathway that could help to improve prognosis and treatment of the disease. Sonja Kessler discovered […] October 30, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 30 Oct 2017 French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexus, based in Lyon, starts trading on Euronext Paris today. The company starts off with a market cap of €47.5M after closing a €19.6M IPO. With the money raised, the company […] October 30, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 30 Oct 2017 Meet the Covagen Co-Founder that Closed Europe’s Biggest Acquisition in 2014 Dragan Grabulovski co-founded the biotech that became 2014’s largest acquisition in Europe. I caught up with him to hear about the journey and what happens to a founder after his or her company is acquired. Dragan Grabulovski was doing a PhD in pharmaceutical sciences at ETH Zurich in the group of Dario Neri when he […] October 30, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email